Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Drug copayment and adherence in chronic heart failure: effect on cost and outcomes.

Cole JA, Norman H, Weatherby LB, Walker AM.

Pharmacotherapy. 2006 Aug;26(8):1157-64.

PMID:
16863491
2.

Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.

Krum H, Haas SJ, Eichhorn E, Ghali J, Gilbert E, Lechat P, Packer M, Roecker E, Verkenne P, Wedel H, Wikstrand J.

Eur Heart J. 2005 Oct;26(20):2154-8. Review.

3.

Economics of treating heart failure.

Mark DB.

Am J Cardiol. 1997 Oct 30;80(8B):33H-38H. Review.

PMID:
9372996
4.

Cost and cost-effectiveness studies in heart failure research.

Weintraub WS, Cole J, Tooley JF.

Am Heart J. 2002 Apr;143(4):565-76. Review.

PMID:
11923792
5.
6.

Clinical and economic factors in the treatment of congestive heart failure.

Andrews R, Cowley AJ.

Pharmacoeconomics. 1995 Feb;7(2):119-27. Review.

PMID:
10155299
7.

Cost-effectiveness of beta-blocker treatment in heart failure.

Gilbert EM.

Rev Cardiovasc Med. 2002;3 Suppl 3:S42-7. Review.

PMID:
12447161
8.

[Beta-blockers in chronic heart failure].

Petruk-Kowalczyk J.

Pol Merkur Lekarski. 2003 Apr;14(82):359-63. Review. Polish.

PMID:
12868203
9.

The pharmacoeconomics of ACE inhibitors in chronic heart failure.

McMurray J, Davie A.

Pharmacoeconomics. 1996 Mar;9(3):188-97. Review.

PMID:
10160096
10.

Heart failure disease management: impact on hospital care, length of stay, and reimbursement.

Discher CL, Klein D, Pierce L, Levine AB, Levine TB.

Congest Heart Fail. 2003 Mar-Apr;9(2):77-83. Review.

11.

ACE inhibitors and health-care economics.

Davie AP, McMurray JJ.

Coron Artery Dis. 1995 Apr;6(4):315-9. Review.

PMID:
7655715
12.

A conceptually based approach to understanding chronically ill patients' responses to medication cost pressures.

Piette JD, Heisler M, Horne R, Caleb Alexander G.

Soc Sci Med. 2006 Feb;62(4):846-57. Review.

PMID:
16095789
13.

The effect of neurohormonal antagonists in reducing heart failure hospitalizations.

Williams RE.

Curr Med Res Opin. 2006 Jan;22(1):139-50. Review.

PMID:
16393440
14.

Economic burden of heart failure: a summary of recent literature.

Lee WC, Chavez YE, Baker T, Luce BR.

Heart Lung. 2004 Nov-Dec;33(6):362-71. Review.

PMID:
15597290
15.

Implications of CIBIS III: a commentary.

Willenheimer R.

J Renin Angiotensin Aldosterone Syst. 2005 Dec;6(3):115-20. Review.

PMID:
16525941
16.

Treatment for chronic heart failure in the elderly: current practice and problems.

Abete P, Testa G, Della-Morte D, Gargiulo G, Galizia G, de Santis D, Magliocca A, Basile C, Cacciatore F.

Heart Fail Rev. 2013 Jul;18(4):529-51. doi: 10.1007/s10741-012-9363-6. Review.

PMID:
23124913
17.

Cost-effectiveness analysis in clinical practice: the case of heart failure.

Rich MW, Nease RF.

Arch Intern Med. 1999 Aug 9-23;159(15):1690-700. Review.

PMID:
10448770
18.

Optimizing treatment and outcomes in acute heart failure: beyond initial triage.

Silver MA, Peacock WF 4th, Diercks DB.

Congest Heart Fail. 2006 May-Jun;12(3):137-45. Review.

19.

The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis.

Sinnott SJ, Buckley C, O'Riordan D, Bradley C, Whelton H.

PLoS One. 2013 May 28;8(5):e64914. doi: 10.1371/journal.pone.0064914. Review.

20.

The impact of angiotensin-converting enzyme inhibitors on managed care: economic, clinical, and humanistic outcomes.

Reeder CE, Gourley GA, Wurtzbacher JD, Reed P.

Am J Manag Care. 2000 Feb;6(3 Suppl):S112-28, quiz S129-31. Review.

Items per page

Supplemental Content

Support Center